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Abstract
Viruses exhibit rapid mutational capacity to trick and infect host cells, sometimes assisted through virus-coded peptides
that counteract host cellular immune defense. Although a large number of compounds have been identified as
inhibiting various viral infections and disease progression, it is urgent to achieve the discovery of more effective agents.
Furthermore, proportionally to the great variety of diseases caused by viruses, very few viral vaccines are available, and
not all are efficient. Thus, new antiviral substances obtained from natural products have been prospected, including
those derived from venomous animals. Venoms are complex mixtures of hundreds of molecules, mostly peptides, that
present a large array of biological activities and evolved to putatively target the biochemical machinery of different
pathogens or host cellular structures. In addition, non-venomous compounds, such as some body fluids of invertebrate
organisms, exhibit antiviral activity. This review provides a panorama of peptides described from animal venoms that
present antiviral activity, thereby reinforcing them as important tools for the development of new therapeutic drugs.
Keywords: Antiretroviral agents, Antiviral agents, HIV, Scorpion venom, Snake venom, Amphibian venom, Insect venom,
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Background
Considering the most common pathologies in humans
and other animals, cardiovascular and infectious diseases
and cancer are among the leading causes of deaths. The
cultural and educational background of affected people
largely influences the prevention and treatment of hu-
man diseases; nevertheless, the availability of new drugs
contributes greatly to mitigating diseases.
More than 200 viruses are known to cause human dis-
eases [1, 2]. Some of them present high public health im-
portance, such as cytomegalovirus (CMV), Epstein-Barr
virus (EBV), hepatitis B and C viruses (HBV and HCV, re-
spectively), herpes simplex virus (HSV), human immuno-
deficiency virus (HIV), rabies virus and Ebola virus. The
most recent worldwide estimates presented by the World
Health Organization (WHO) reported 1.5 million deaths
caused by HIV in 2012, 400 million people living with
hepatitis B or C, 80% of liver cancer deaths caused by
hepatitis viruses, 500 thousand cases of cervical cancer
caused by HPV infection, and over 250 thousand cervical
cancer deaths each year [3].
The very few antiviral drugs commercially available
can induce severe and considerable adverse effects, espe-
cially to those patients receiving lifelong treatment for
diseases such as HIV. Furthermore, viruses possess rapid
mutational capacity to trick and infect host cells. All
these facts together have propelled the prospection for
new antiviral drugs, particularly from natural products,
as they constitute more than 25% of the new drug proto-
types approved in the last decades [4]. Among sources
of natural products, animal venoms have revealed a great
potential for drug discovery [5–7], and despite the harm-
ful action mechanism of animal venoms, most of them
have components holding potential medicinal properties
to cure diseases.
It is widely reported in the literature that animal venoms
are rich sources of antimicrobial substances, and contain a
vast array of active biological compounds with distinct
chemical structures [8]. Thus, antimicrobial peptides
(AMPs)— a diversified group of peptides that exert essen-
tial function in the innate immune host response, when
invaded by pathogenic organisms, such as bacteria, fungi
and virus — are considered the first line of defense of
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many organisms, including plants, insects, bacteria and
vertebrates [9, 10].
Possible action mechanism of antiviral
compounds
Some peptides exhibit direct virucidal activity; others dis-
turb attachment of virus particles to the cell membrane
surface or interfere with the virus replication. Because of
the limited efficiency of commonly used drugs and emer-
ging resistance of viruses, antiviral peptides may have the
potential for development as putative therapeutic agents
[11]. In addition to their reduced market availability, the
collateral effects and toxicity of the synthetic antiviral
drugs have triggered an expanded search for natural com-
pounds displaying antiviral activities [12, 13]. Any com-
pound to be utilized as an antiviral should comply with the
virus pathways during the cellular infectious cycle. Initially,
any RNA or DNA virus, enveloped or not, expresses glyco-
proteins that are responsible for the interaction with sur-
face molecules, receptors, usually glycosylated proteins,
integrated in the host cell membrane. At this step, any po-
tential antiviral candidate must compete for the cell recep-
tor by inhibiting the virus attachment to the cell
membrane, thereby aborting the viral infection.
Other candidates may act intracellularly by interacting
with the virion capsid to prevent its decapsidation; there-
fore, the viral nucleic acid would not be freed and tran-
scribed. Concerning retroviruses, the antiviral candidates
can act by inhibiting (i) the viral reverse transcriptase ac-
tivity; (ii) the pre-integration complex, thus avoiding the
transport of circular viral DNA to the nucleus; (iii) and
also by inhibiting the action of the viral integrase, which
would not allow the viral DNA to integrate into the cellu-
lar chromosome. The proviral DNA, after transcription, is
transduced into a polyprotein that requires the viral prote-
ase in order to generate small proteins to assemble the
viral capsid. In this manner, an antiviral compound could
inhibit the viral protease by blocking the retroviral mor-
phogenesis (Fig. 1) [14]. Some retroviral proteins play a
major role in the pathogenesis, by down regulation of
CD4 and MHC molecules of the host cell, driving them to
the proteasome for degradation. If supposed antiviral can-
didates target these viral proteins, HIV-1 Nef, Tat and Vpr,
their actions can be restrained. All the mentioned mecha-
nisms are directly performed by retroviral molecules [15],
but other mechanisms could also be triggered, such as
those involved in the innate immune system, e.g. (i) the
induction of toll-like receptor expression, that interacts
Fig. 1 Action mechanism of animal venom peptides or derivatives at different retrovirus replication cycle phases. (1) The ChTx and Scyllatoxin-based
mimetics, such as CD4M33, inhibit the attachment of the viral glycoprotein (gp120) to the host cell receptor CD4. (1a) The peptides cecropin A,
magainin 2, papuamide A, dermaseptin DS4, caerins 1.1 and 1.9 and maculation 1.1 disintegrate the viral envelope. (1b and 1c) The peptides
CD4M33, BmKn2, Kn2-7, polyphemusin, tachyplesin, immunokine and p3bv obstruct the interaction of the viral gp 120 to the CXCR4 and CCR5
co-receptors. (2) The peptides miramides A–H inhibit the fusion of the viral envelope to the host cell membrane. (3) The peptides melittin, didemnis A,
B and C interfere with the reverse transcription process, aborting the synthesis of double-stranded viral DNA. (6) The peptides hecate and TVS-LAO act
in the post-translation process, in the cleavage of the GAG/POL protein precursor thus interfering in the assembly of the viral capsid and in the
organization of the polymerase complex
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with viral nucleic acid, or (ii) production of cytokines that
stimulate the action of T cytotoxic cells, and NK cells, and
even host cell expression of the major histocompatibility
complex molecules, in order to present viral peptides to
the other cells of the immune system [16]. Furthermore,
antiviral compounds may activate innate restriction fac-
tors coded by the host cell [17].
Mechanisms of viral resistance to drugs
The viral DNA integration in the host cell chromosome
represents the major problem to be overcome in a retro-
viral infection. Until now, there is no available drug cap-
able of completely clearing the virus from the host [18].
Furthermore, silent retroviral infection is hidden at ana-
tomical sites that are difficult to reach by drugs, such as
the gut-associated lymphoid tissues, lymph nodes and
central nervous system. Infected cells, including macro-
phages, are quiescent in these tissues and it is not
known when they will activate and release new viral pro-
genies. Another challenge for an antiviral candidate is
posed by the mutation rate of viral genes, mainly among
RNA virus, due to the polymerase synthesis error. This
is much more intriguing among retroviruses, as the initial
virion genome, maintained in quiescent cells in “sanctuary
niche”, are distinct, mutated from each round of cell in-
fection. Thus, in each cycle of viral infection, the hijacked
cell produces a growing number of recombinant new
virions [19].
Antiviral peptides obtained from animal venoms
Scorpion venoms
The arachnid venoms, utilized as a tool for defense and
attack, by killing or immobilizing their prey for feeding
or their possible competitors and predators, are composed
of a rich molecular diversity and complex mixture, with an
intricate protein and peptide expression by mechanisms of
gene regulation still under investigation [20, 21]. Scorpion
venoms have been exhaustively studied, mainly due to
the clinical effects after envenomation in humans, which
sometimes lead to death [22]. Paradoxically, biotechno-
logical applications are devised by the increased under-
standing of the action mechanisms of venom components,
and therefore, many research works deal with the gener-
ation of new drugs based on the structure and function of
molecules found in these venoms [23–25].
With the rapid increase in the number of characterized
scorpion venom compounds, many new drug candidates
have been identified as potential medicines to deal with
emerging medical global threats [8, 20]. In scorpions
the biologically active peptides are classified as disulfide-
bridged peptides (DBPs) and non-disulfide-bridged peptides
(NDBPs) [26, 27], with the former being the main compo-
nents of scorpion venoms, responsible for the neurotoxic
symptoms and signs observed during scorpionism. Usually
these DBPs target the ion channels of excitable and
non-excitable cell membranes. These properties make
these molecules interesting prototypes of drugs for the
treatment of diverse diseases, particularly those affect-
ing the neural system [8].
In relation to the activity of scorpion venom compounds
against retroviruses, such as HIV/SIV, it has been reported
that some DBPs can bind to HIV gp120 glycoprotein due
to molecular mimicry of lentiviruses host cell CD4+ recep-
tor. As a result, they abolish the gp120-CD4 interaction,
which is essential to initiate the conformational changes
in the viral envelope that trigger viral entry into host cells
[28]. These CD4 mimetic scorpion toxins contain about
30 amino acid residues, with three or four disulfide brid-
ges, characterized by the cysteine-stabilized α/β motif
(CS-α/β), in which a β-turn between the two β-strands in
these peptides resembles the CDR2 loop of CD4.
Both charybdotoxin (ChTx) and scyllatoxin, isolated
from Leiurus quinquestriatus hebraeus venom, present
the CS-α/β motif and are capable of blocking K+ channels
[29–32]. These toxins have been used effectively as molecu-
lar scaffolds for gp120-CD4 interaction assays [28, 33, 34].
Since the amino acid residues Phe43 and Arg59 of CD4 were
shown to be critical for CD4 binding to gp120, equivalent
amino acid residues were added to the new compounds.
Examples of mimetic peptides using ChTx as a scaffold
include CD4M and TXM1, with 33 and 32 amino acid
residues, respectively [33, 35]. Among the main modifi-
cations, the CD4 CDR2 loop sequence
40QGSF43 was
inserted in the equivalent position of the β-turn of ChTx.
Thus, Phe28 of CD4M, or Phe27 of TXM1, would function
as Phe43 in CD4. The remaining sequence is similar be-
tween the two analogs, except in two positions: Arg20
in TXM1 (Arg25 in ChTx) is replaced by Lys in CD4M,
and TXM1 has a Gly1 as the N-terminal residue in
place of Val1-Ser2 residues in CD4M. Thus, the charged
N-terminus of the Gly1 residue in TXM1 is in a pos-
ition similar to that of the charged side-chain of Arg59
in CD4 [33]. CD4M was able to inhibit gp120 binding
to CD4 with an IC50 value of 20 μM [35]. Likewise,
TXM1 also competed with CD4 for gp120 binding, be-
sides causing a CD4-like enhancement in gp120 binding
to the antibody 17b [33]. Subsequently, other CD4 mi-
metics exhibiting gp120 affinity were successfully gener-
ated by phage epitope randomization of the β-turn loop in
a ChTx-based scaffold [28].
As to scyllatoxin scaffold-based mimetics, a 27-amino
acid residue miniprotein named CD4M3 was constructed,
which inhibited CD4 binding to gp120 with an IC50 value
of 40 μM [34]. Structural and functional analysis
performed with CD4M3 suggested additional mutations
that, once incorporated in the new compound (CD4M9),
caused an increased affinity for gp120, with IC50 values of
0.1–1.0 μM, depending on the viral strains. Additionally,
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CD4M9 inhibited infection of CD4+ cells by different
HIV-1 strains [34]. Its β-turn sequence (20AGSF23) is simi-
lar to that of TXM1. After that, based on CD4M9 struc-
tural analysis, a potent mimetic with bona fide CD4-like
properties was synthesized [36]. Denominated CD4M33,
it inhibited CD4-gp120 binding in different viral strains
with 4.0–7.5 nM IC50, with these values being comparable
to those obtained with CD4. CDM33 also inhibited HIV-1
cell-cell fusion and infection of cells expressing CD4 and
either the CCR5 or CXCR4 co-receptors at similar con-
centrations to CD4 [36]. Its three dimensional structure
was further analyzed in complex with gp120 [37]. Then,
another analog was designed, denominated F23, which
differs from CD4M33 due to the presence of Phe23 in
replacement by biphenylalanine in position 23 (Bip23).
The authors showed that F23 had higher mimicry of
CD4 than CD4M33. In addition, F23 presented increased
neutralization against isolates of phylogenetically related
primate lentiviruses [37].
The scorpion venom AMPs belong to NDBPs; many of
them and their analogs exert strong antiviral activity, as
shown in Table 1. Some of these compounds act by dir-
ect rupture of the viral envelope, thereby decreasing viral
infectivity [8]. AMPs could also prevent or block the vir-
ion from entering into the cell by occupying cell recep-
tors utilized by the viral glycoproteins [38]. Other AMPs
do not compete with viral glycoproteins to get attached to
cell receptors. Instead, they can cross the cell lipoprotein
membrane and internalize themselves in the cytoplasm
and organelles, yielding alterations in the profile of host
cells that can enhance the defense against the virus or
may also block the expression of viral genes in the host
cell, halting viral dissemination to other cells [9].
Mucroporin is a cationic 17-amino-acid residue AMP
isolated from Lychas mucronatus venom. One of its de-
rivatives, named mucroporin-M1, has an enhanced net
positive charge, and besides having antibacterial activity,
presented antiviral activity against Measles, SARS-CoV
and Influenza H5N1 viruses (Table 1), possibly through
a direct interaction with the virus envelope [39]. Addition-
ally, it has been shown to reduce the production of HBV
antigens and viral DNA in cell culture microenvironment
and also to hinder HBV infection in mouse models [40].
The molecular mechanism implicated reveals the specific
activation of mitogen-activated protein kinases (MAPKs)
leading to down-regulation of HNF4α expression and con-
sequently less binding to the HBV pre-core/core promoter
region [40]. Mucroporin-M1 also presented anti-HIV-1
activity [38].
An amphipathic α-helical peptide, Hp1090, was screened
from the cDNA library of Heterometrus petersii venomous
gland. This 13-amino-acid residue NDBP inhibited the
HCV infection (Table 1), acting as a viricide against HCV
particles and preventing the initiation of HCV infection by
permeabilizing the viral envelope and decreasing virus
infectivity [41]. Also from H. petersii venom gland cDNA
library, other α-helical NDBPs were synthesized. Two of
them, Hp1036 and Hp1239, exhibited potent virucidal
activity against HSV-1 (Table 1) [42]. They showed inhibi-
tory effects on multiple steps of the virus replication cycle,
caused the destruction of the viral morphology and also en-
tered the infected cells where they reduced viral infectivity.
From the cDNA library of Mesobuthus martensii
venom gland, a compound denominated BmKn2 — with
13 amino acid residues — was cloned and synthesized.
Based on its sequence, Kn2-7 was designed by making
Table 1 Scorpion peptides and derivatives with antiviral activity
Scorpion Peptide name Virus EC50 Reference
Lychas mucronatus Mucroporin-M1 MeV 7.15 μg/mL (3.52 μM) [39]
SARS-CoV 14.46 μg/mL (7.12 μM) [39]
H5N1 2.10 μg/mL (1.03 μM) [39]
HBV – [40]
HIV-1 – [38]
Heterometrus petersii Hp1090 HCV 7.62 μg/mL (5.0 μM) [41]
Hp1036 HSV-1 0.43 ± 0.09 μM [42]
Hp1239 HSV-1 0.41 ± 0.06 μM [42]
Mesobuthus martensii Kn2-7 HIV-1 2.76 μg/mL (1.65 μM) [38]
Bmkn2 HIV-1 – [38]
Chaerilus tryznai Ctry2459 HCV 1.84 μg/mL [43]
Ctry2459-H2 HCV 1.08 μg/mL [43]
Ctry2459-H3 HCV 0.85 μg/mL [43]
EC50 peptide concentration required to reduce virus infection by 50%, HIV-1 human immunodeficiency virus type 1, MeV measles virus, HBV hepatitis B virus, HCV
hepatitis C virus, SARS-CoV severe acute respiratory syndrome/coronavirus, H5N1 influenza virus, HSV-1 herpes simplex virus type 1. Adapted from Hmed et al. [8]
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the substitutions G3K, A4R and S10R, enhancing its net
positive charge and α-helix structure [38]. Both com-
pounds exerted anti-HIV-1 activity through inhibition of
chemokine receptors CCR5- and CXCR4-mediated ac-
tivities and replication of the viruses, of which Kn2-7
was the most potent (Table 1) [38].
Another NDBP, screened from Chaerilus tryznai scor-
pion venom gland, Ctry2459, was able to inhibit initial
HCV infection in Huh7.5.1 cells by inactivating infec-
tious viral particles (Table 1) [43]. However, due to the
low bioavailability of this 13-amino-acid residue peptide,
Ctry2459 could not suppress an established infection.
Thus, in order to enhance the helicity, amphiphilicity
and endosomal escape of peptides, the authors designed
histidine-rich peptides based on a Ctry2459 template.
Denominated Ctry2459-H2 and Ctry2459-H3, they were
more effective against HCV than Ctry2459 (Table 1), sig-
nificantly reducing intracellular viral production. Unlike
Ctry2459, these analogs reduced the viral RNA by 40
and 70%, respectively; however, Ctry2459 diminished
viral infectivity in a manner similar to that of wild-type
peptide [43].
Recently, the antiviral activities of Scorpio maurus pal-
matus and Androctonus australis crude venoms were
shown against HCV. They presented IC50 values of 6.3
± 1.6 and 88.3 ± 5.8 μg/mL, respectively. S. maurus pal-
matus venom was considered a good natural source for
characterizing new anti-HCV agents targeting the entry
step, since it impaired HCV infectivity in cell culture,
but not intracellularly, through a virucidal effect. This ef-
fect was not inhibited by a metalloprotease inhibitor or
heating at 60 °C [44].
Snake venoms
Snake venoms are composed of a mixture of proteins,
peptides (90–95%), free amino acids, nucleotides, lipids,
carbohydrates and metallic elements coupled to proteins
(5%) [45]. Some studies have reported the antiviral activ-
ity of snake venoms and their components against mea-
sles virus, Sendai virus, dengue virus (DENV), yellow
fever virus (YFV) and HIV [46–50]. Thus, snake venoms
are sources of promising candidates for new antiviral
drugs (Table 2). In relation to antiretroviral activity, the
benefits of treating a patient with multidrug-resistant
HIV with a snake venom preparation in addition to the
antiretroviral therapy were demonstrated in clinical prac-
tice [51]. The response was a decreased viral load and ele-
vated T CD4+cell count. The authors suggest that this
activity may be related to the presence of some snake
venom molecules that are homologous to HIV-1 glycopro-
tein or proteases [51, 52].
This homology occurs between the 30–40 highly con-
served amino acid residues of snake venom neurotoxins
long loop and the sequence 164–174 of short segment
HIV-1 gp120. As a result, both may compete for the
same receptor or binding site and present anti-HIV ac-
tivity [50]. The sequence homology between HIV gp120
and snake neurotoxins, such as cobratoxin and bun-
garotoxin, had generated some antiretroviral patents
[53–55]. Linking the gp120 fragment to the HIV pep-
tide fusion inhibitors (fragments of gp41 ectodomains)
was shown to improve their anti-HIV efficacy [56]. Be-
sides structural homology, other action mechanisms of
snake venoms against HIV are also discussed in the lit-
erature, such as catalytic/inhibitory activity through en-
zymes, binding interference (receptor/enzyme), and
induction/interaction at the membrane level [50].
The L-amino acid oxidases (LAAOs or LAOs, EC1.4.3.2),
which constitute one of the most studied main components
of snake venoms, are oxidoreductase flavoenzymes with
molecular masses around 110 to 150 kDa and are usually
non-covalently linked homodimeric glycoproteins [57, 58].
These compounds are widely distributed in other organ-
isms and play an important role in biological activities such
as apoptosis induction, cytotoxicity, inhibition or induction
of platelet aggregation, hemorrhaging, hemolysis and
edema, as well as anti-HIV, antimicrobial and antipara-
sitic activities [59]. TSV-LAO, characterized from Tri-
meresurus stejnegeri snake venom, seems to be the first
snake venom LAO reported to present antiviral activity
(Table 2) [60].
TSV-LAO is a glycoprotein with a molecular weight of
about 58 kDa that also forms homodimers, similarly to
LAOs from other snake venoms. Its precursor sequence,
obtained by cDNA analysis, codes for a polypeptide of
516 amino acid residues, including an 18-amino-acid po-
tential signal peptide that is identical to those of LAOs
from other snake species. TSV-LAO inhibited HIV-1 in-
fection and replication in a dose-dependent manner, and
seems to act at nanomolar concentrations by inhibiting
syncytium formation (EC50 of 1.5 nM) and HIV-1 p24
antigen expression (EC50 of 4.1 nM) [60].
Additionally, another LAO, isolated from Bothrops jar-
araca venom and denominated BjarLAAO-I (Table 2),
reduced the viral load in cells infected with dengue virus
type 3 strain exposed to the toxin in comparison to con-
trols [61]. Its cDNA-deduced sequence has 484 amino
acid residues and is similar to other snake venom LAOs.
These flavoenzymes also produce hydrogen peroxide
(H2O2) as a free radical, which appears to enhance their
antiviral activity [60].
Other compounds found in snake venoms that exhibit
antiviral activity are the phospholipases A2 (PLA2). Among
their biological effects, they seem to interact with the host
cells and prevent the intracellular release of virus capsid
protein, suggesting that they block viral entry into the cells
before virion uncoating [7, 49, 62]. The PLA2 isolated from
Crotalus durissus terrificus venom (PLA2-Cdt, Table 2)
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Table 2 Examples of animal peptides presenting antiviral activity
Source Species Peptide name Virus Action mechanism Reference
Frog Xenopus laevis Magainin 1 and 2 HSV-1 and HSV-2 Cellular target [115]
Frog Rana brevipodaporsa Brevinin-1 HSV Viral inactivation [116]
Frog Phyllomedusa Dermaseptin S4 HSV-2 Viral envelope disruption [69]
Frog Phyllomedusa Dermaseptin DS4 HIV-1 Viral envelope disruption [117]
Frog – Dermaseptin S4 HSV-1 Viral membrane disruption [118]
Frog Litoria caerulea Caerin 1.1 HIV Viral envelope disruption [70]
Frog Litoria chloris Caerin 1.9 HIV Viral envelope disruption [70]
Frog Litoria genimaculata Maculatin 1.1 HIV Viral envelope disruption [70]
Insect Vespula lewisii MP7-NH2 HSV Viral envelope disruption [74]




Insect Synthetic (from melittin) Hecate HSV Cellular target [83]
Insect Bee venom bvPLA2 HIV Virion entry blocking into
host cell
[65]
Insect Synthetic (from bvPLA2) p3bv HIV HIV glycoprotein fusion
inhibition to CXCR4 cell
receptor
[76]
Insect Calliphora vicina Alloferons 1 and 2 IAV/HSV Immunomodulatory activity [88]
Insect Hyalophora cecropia Cecropin A-magainin 2 HIV Virion entry blocking into
host cell
[85]
Ophidian Trimeresurus stejnegeri TSV-LAO HIV-1 Syncytium formation inhibition
and HIV-1 p24 antigen reduction
[60]
Ophidian Bothrops jararaca BjarLAAO-I DENV-3 Infected cells reduction [61]
Ophidian Crotalus durissus terrificus PLA2-Cdt DENV, YFV Virus envelope cleavage and
protein destabilization
[48, 63]
HIV Gag p24 processing inhibition [62, 64]
Ophidian Bothrops leucurus BlK-PLA2; BlD-PLA2 DENV Viral RNA levels reduction [65]
Ophidian Naja kaouthia (Naja
siamensis)
Immunokine HIV CCR5 and CXCR4 receptors
interaction
[7, 66]
Marine sponge Sidonops microspinosa Microspinosamide HIV Cytopathic effect inhibition [111]
Marine sponge Siliquariaspongia mirabilis
and Stelletta clavosa
Mirabamides A-H HIV Viral glycoprotein fusion
neutralization to the cell
receptors
[94, 95]
Marine sponge Homophymia sp. Homophymine A HIV Virion entry inhibition [96]
Marine sponge Theonella sp. Papuamides A and B HIV Virion entry inhibition [106]
Marine sponge Theonella swinhoe Theopapuamide A HIV Virion entry inhibition [105, 106]
Marine sponge T. swinhoe and T. cupola Koshikamides F, H HIV Virion entry inhibition [104]
Marine sponge Siliquariaspongia mirabilis Theopapuamide B HIV Viral envelope disruption [108]
Marine sponge Siliquariaspongia mirabilis Celebesides A–C HIV Virion entry inhibition [108]
Marine sponge Callipelta sp. Callipeltin A HIV Virion entry inhibition [109]
Marine sponge Neamphius huxleyi Neamphamide A HIV Virion entry inhibition [110]




Fish Pleuronectes americanus Pa-MAP HSV Viral envelope interaction [91, 92]
Tunicate Trididemnum solidum Didemnins A, B and C HSV-1 and 2; coxsackie
virus A-21 and equine
rhinovirus
Protein, DNA and RNA
synthesis inhibition
[97]
HIV human immunodeficiency virus, HSV herpes simplex virus, IAV influenza virus, VSV vesicular stomatitis virus, DENV dengue virus. Adapted from Jenssen et al.
[9] and Mulder et al. [77]
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inhibited both DENV and YFV in Vero E6 cells [48]. This
PLA2 is part of crotoxin, a heterodimeric protein com-
posed of two different subunits non-covalently linked: the
basic PLA2 (~16.4 kDa) and the acidic protein crotapotin
(~9.0 kDa) [48].
The mechanism proposed for PLA2-Cdt antiviral activ-
ity involves the cleavage of the glycerophospholipid virus
envelope and protein destabilization on the virion surface,
which partially exposes the genomic RNA and culminates
with viral inactivation, making it unable to access the cell
receptor [63]. PLA2-Cdt also showed in vitro activity
against HIV (Table 2) [62, 64], as well as the snake venom
PLA2s NmmCMIII from Naja mossambica mossambica,
taipoxin from Oxyuranus scutellatus, and nigexine from
Naja nigricollis [49]. Additionally, the PLA2 variants,
Lys49 and Asp49, denominated BlK-PLA2 and BlD-PLA2,
from Bothrops leucurus venom (Table 2), reduced dengue
viral RNA in cells treated with these compounds, and pre-
sented cytotoxic activity against DENV-infected cells in
vitro [65]. BlK-PLA2 and BlD-PLA2 have 121 and 122
amino acid residues, respectively, including seven disulfide
bonds.
Another example of the antiviral effect of biomolecules
extracted from snake venoms are the metalloprotease in-
hibitors, which could prevent the production of new HIV
particles by inhibiting the viral proteases [50]. In addition,
Immunokine® (OXO Chemie, Thailand), an oxidized de-
rivative of the α-toxin extracted from Naja siamensis
venom (Table 2), has been shown to inhibit infection of
lymphocytes by HIV through the chemokine receptors
CCR5 and CXCR4 [7, 66].
Anuran skin peptides
Many reports detail potent antiviral activity of amphibian
skin secretions. Such skin secretions constitute the am-
phibians’ first line of defense, consisting of their innate
immunity. The secretions produced by the anuran skin
granular glands have been screened for many biological
activities, including antimicrobial, antineoplastic, antiviral,
contraceptive and anthelminthic activities [67, 68].
The dermaseptin family of antimicrobial peptides com-
prise 24–34 amino acids, exhibiting a linear polycationic
molecule disposed as an amphiphilic α-helical structure
when associated with a lipid cell bilayer. Bergaoui et al.
[69] described the dermaseptin S4, a chemically synthesized
28-amino-acid drug derived from an amphibian skin anti-
microbial peptide, exhibiting anti-herpetic activity (HSV
type 2), with reduced cytotoxic effects after biochemical
modifications of the original peptide. It also reduced in
vitro HIV-1 infection of an established cell line, P4-
CCR5, expressing CD4, CCR5, and CXCR4 HIV-1 cell
receptors and, primary T lymphocytes, being capable of
acting on both R5 and X4 tropic HIV-1 virions. Upon
insertion in the viral envelope, the dermaseptin S4 dis-
rupts the virion [69].
Caerin 1.1, caerin 1.9 and maculatin 1.1, peptides also
derived from the skin secretions of the amphibians Litoria
caerulea, Litoria chloris and Litoria genimaculata, re-
spectively, completely abolished HIV infection of T cells,
after a few minutes of virion exposure to these modified
peptides, which disintegrates the viral envelope, prevent-
ing viral fusion to the cell membrane. Furthermore, these
molecules obstructed viral transfection from dendritic
cells to T cells. Caerin peptides are composed of 25 amino
acid residues in their structure, including four central
amino acid residues not present in maculatin peptides. In
lipid bilayer membranes, these peptides are adjusted to
two α-helices, interlinked by a flexible hinge region limited
by Pro15 and Pro19, which determine the disruption of
viral envelope and cell membrane [70].
Insect venoms
Mastoparan is a tetradecapeptide present in wasp (Ves-
pula lewisii) venom [71] that forms amphipathic helical
structures that insert into lipid bilayers of bacteria, eryth-
rocytes, mast cells and others, forming pores [72, 73].
Mastoparan-7, a mastoparan analogue, displayed a wide
spectrum of antiviral activity against enveloped viruses of
five different families (Rhabdoviridae, Poxviridae, Flaviri-
dae, Paramyxoviridae and Herpesviridae) in in vitro assays
(Table 2). Structural studies have indicated pore formation
by the insertion of the mastoporan amphiphilic α helix
into the viral lipidic envelope, causing its disruption [74].
HIV virions usually infect the host cells in the genital
mucosae, by infecting macrophages, being denominated
M-tropic virus; after migrating to the lymph nodes, they
infect T lymphocytes, changing into T-tropic virus [75].
Based on the HIV tropism, a phospholipase A2 from bee
venom, bvPLA2, blocked the replication of both M and
T-tropic HIV virions [65], while a small peptide derived
from bvPLA2, the p3bv, exclusively inhibited the repli-
cation of T-tropic virus, behaving as a ligand for the
HIV-1 co-receptor CXCR4 [49, 76] (Table 2).
AMPs isolated from invertebrate organisms presented
augmented antiviral activity in human diseases. Such pep-
tides enclose melittin, cecropin and alloferon molecules
[77] (Table 2). Melittin, isolated from honey bee (Apis mel-
lifera) venom, is an amphipathic peptide composed of 26
amino acid residues, arranged in two α helical segments.
Inserted in nanoparticles, melittin exhibited virucidal activ-
ity against HIV-1 in the VK2 cell line, an epithelial vaginal
cell line, and also inhibited HIV infection in TZM-bl
reporter cells (HeLa cell line expressing HIV receptors)
[78–80]. Among other antiretroviral mechanisms, melittin
complemented the azidovudin reverse transcription in-
hibition [81, 82]. Hecate, an analogue of melittin, select-
ively reduced the protein biosynthesis of virus-specified
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glycoproteins B, C, D, and H of the HSV type 1 [83]. The
mechanism is similar to the one detected among HIV-1
infected lymphoblastic cells, previously treated with melit-
tin, by the intervention in the processing of the gag/pol
protein precursor. Therefore, specific intracellular events
are targeted by melittin and its derivatives [82, 84].
Cecropins, isolated mostly from the hemolymph of in-
fected pupae of the silk moth Hyalophora cecropia, but
also from other insects, tunicates and Ascaris nematodes,
are a family of AMPs, containing 35–37 amino acid resi-
dues arranged in two amphiphilic α-helices linked by a
Gly-Pro hinge. Synthetic hybrid peptides, namely cecropin
A (1–8)-magainin 2 (1–12), exhibited potent antiviral ac-
tivity by a mechanism mainly based on the compound
hydrophobicity and α-helical content, inhibiting the virus-
host cell fusion [85] (Table 2).
Alloferon 1 and 2 are peptides constituted of 12–13
amino acid residues, isolated from the hemolymph of the
blowfly Calliphora vicina. Alloferons exert immunomodu-
latory activities to control infection by the human influ-
enza virus in mice model of lethal pulmonary infection
[75], whereas their derivatives also inhibited in vitro HSV
replication in Vero cells [86, 87] (Table 2). These peptides
also displayed a relevant role in the innate immunity, be-
ing considered prospective peptides for the pharmaceut-
ical industry [88, 89].
Peptides from marine organisms
Sea organisms are also promising sources of antiviral
cationic peptides. They present a broad spectrum of
antiviral activity, while one single peptide may present
activity against different viruses and other pathogens.
The promiscuous antifreeze Pa-MAP peptide, which con-
sists of an α-helix composed of 11 amino acid residues,
was isolated from the polar fish Pleuronectes americanus
(Table 2). The Pa-MAP exerted antimicrobial activity
against bacteria, fungi, neoplastic cells, and also interacted
with the viral envelope of the HSV types 1 and 2, inhibit-
ing the infection of susceptible cells [77, 90–92].
Some sponge species contain linear or cyclic bioactive
peptides composed of atypical amino acid residues, gen-
erating unique structures that are rarely found in terres-
trial organisms [90, 93]. These compounds, particularly
the cyclic depsipeptides mirabamides A-H, isolated from
Siliquaria spongia mirabilis and Stelletta clavosa, obstruct
the HIV-1 virion entry into TZM-bl cells, thus neutraliz-
ing the viral glycoprotein fusion for expressing CD4 and
CCR5 HIV cell receptors [94, 95] (Table 2). Peptide con-
centrations between 40 and 140 nM were sufficient to in-
hibit infection by 50% (IC50). Another cyclodepsipeptide,
homophymine A, obtained from Homophymia sp., con-
ferred 50% cell protection at 75 nM concentration against
HIV-1 infection in vitro [96] (Table 2).
Discovered in the early 1980s, didemnins A, B and C
from the Caribbean tunicate Trididemnum solidum were
the first antiviral marine depsipeptides described. Didem-
nins were effective against vaccinia virus, HSV type 1 and
2, coxsackie virus A-21 and equine rhinovirus, presenting
strong activity at low doses [97]. Furthermore, these pep-
tides were active in in vivo assays in a rat model infected
with herpes simplex virus, reducing the skin lesions after
topical administration [98]. Didemnins inhibit protein,
DNA and RNA synthesis in cells [99, 100]. The protein
synthesis inhibition mechanism may be related to the
binding of didemnins to the elongation factor 1 alpha
(EF-1 alpha) [101]. Didemnin B underwent phases I
and II of clinical trials in the 1980s, but presented low
selectivity and therapeutic index, as well as toxic side
effects [102]. Dehydrodidemnin B (Aplidin®, Pharma Mar
SA, Spain) is currently under phase III of clinical trials as
an anticancer drug against multiple myeloma and T-cell
lymphoma [103].
Several antiviral peptides and depsipeptides have been
described in marine sponges from the genus Theonella
sp.: koshikamides F and H isolated from T. swinhoei and
T. cupola [104]; papuamides A and B, and theopapuamide
A from Theonella sp. and T. swinhoei, respectively
[105–107]. All of them inhibited HIV entry into T cells.
Theopapuamide B was isolated from an Indonesian
sponge, Siliquariaspongia mirabilis, and was also able
to inhibit HIV-1 entry into host cells [108]. Papuamide
A presented antiviral activity not only against HIV-1, but
also against vesicular stomatitis virus and amphotropic
murine leukemia virus. Due to its tyrosine residue and the
presence of a hydrophobic tail, the peptide may insert into
the viral membrane, causing its rupture [105].
Other peptides from marine sponges that inhibit HIV-1
entry into host cells are: callipeltin A, isolated from
sponges of the genus Callipelta, which displayed antiviral
activity with a high selectivity index (29) between the virus
and host cells (SI ratio 50% cytotoxic dose [CD50]/ED50)
[109]; celebesides A-C from Siliquariaspongia mirabilis
[108]; neamphamide A, from Neamphius huxleyi, a com-
pound with structural similarities to callipeptins and papua-
mides that exhibited low toxicity to host cells and a selectivity
index above 10 [110]; and microspinosamide, isolated from
Sidonops microspinosa [111].
Marine arthropod species have also yielded antiviral
peptides, tachyplesin and polyphemusin (T140), and shown
anti-HIV-1 activity by attachment to the chemokine recep-
tor, CXCR4, which is also the viral T cell co-receptor. He-
mocytes of horseshoe crabs (Tachypleus tridentatus and
Limulus polyphemus) are an abundant source of tachy-
plesin and polyphemusin. The tachyplesin consists of
17–18 amino acid residues, primarily arranged in three
tandem repeats of a tetrapeptide, hydrophobic amino
acid-Cys-aromatic amino acid-Arg and an amidated
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C-terminus, while the polyphemusin analog, T140, is
composed of 14 amino acid residues, exposing an anti-
parallel β-sheet conformation stabilized by a disulfide
bridge between Cys4 and Cys13 [112, 113].
Conclusions
As a consequence of the scarcity of new families of anti-
viral drugs, pharmaceutical companies have strengthened
their efforts to increase developments of known current
drugs, resulting in little or even no improvement to the
existing therapies. These new patent protections guarantee
the rights to the same stakeholders who are charging high
consumer prices due to the lack of competition [114]. At
the same time, the growing demand for new drugs and
natural therapeutic products is a matter of extreme neces-
sity to face the emergency of multiresistant viral patho-
gens. More than 45 compounds obtained from vertebrate
and invertebrate organisms presented in vitro or in vivo
antiviral activity. Although none of those has yet been
launched on the market as an antiviral drug, they present
chemical structures completely different from the current
drugs used in therapy, despite acting on similar targets.
Those compounds may lead to new classes of therapeutic
drugs after additional chemical and pharmacological
studies.
Emerging and reemerging viruses of medical relevance
challenge health authorities all around the planet. Some
viral vaccines have taken too long to be designed and ap-
proved for human and animal utilization, and even in
some cases could not be developed. Preventive and cura-
tive measures should always be in the hands of health
authorities to ensure control of epidemics, such as the
recent Ebola virus in Africa or arboviruses, particularly
in Brazil – represented by the dengue, chikungunya and
Zika viruses – or worldwide pandemics, such as influenza
and HIV. Therefore, prospection, screening and all other
phases of biological activity, validation, clinical develop-
ment of animal peptides represent an essential scientific
investment for protecting and perpetuating humankind.
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